StockWatch
·
Pharmaceutical Preparations
DealsNov 20, 2026, 04:46 PM

Apimeds Pharmaceuticals Amends Apitox Rights Deal, Issues 350K Shares

AI Summary

Apimeds Pharmaceuticals US, Inc. (APUS) has amended its Assignment and Transfer Agreement with FreeT Inc. regarding certain Apitox Rights. The amendment clarifies the consideration, which includes an initial issuance of 350,000 APUS common shares by December 1, 2026. An independent valuation will determine if additional cash, stock, or a combination is due within 30 days of its completion. The initial share issuance is unregistered, relying on Section 4(a)(2) of the Securities Act.

Key Highlights

  • Apimeds Pharmaceuticals US, Inc. amended its Apitox Rights Assignment Agreement with FreeT Inc.
  • Initial payment includes 350,000 shares of APUS common stock due by December 1, 2026.
  • An independent valuation will determine fair value of Assigned Rights.
  • Additional consideration (cash/stock) may be paid if valuation exceeds initial payment.
  • Issuance of shares is unregistered, under Securities Act Section 4(a)(2) exemption.